SALAJKA, František, Miloš PEŠEK, Jana KREJČÍ, Jana SKŘIČKOVÁ, Petr ZATLOUKAL, Leona KOUBKOVÁ, Ivona GRYGÁRKOVÁ, Michal HRNČIARIK and Michal ŠTÍCHA. The analysis of influence of clinical predictors on the results of treatment with erlotinib in patients with advanced non-small cell lung cancer. In Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer. 2011. ISSN 1556-0864.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The analysis of influence of clinical predictors on the results of treatment with erlotinib in patients with advanced non-small cell lung cancer.
Authors SALAJKA, František (203 Czech Republic, guarantor), Miloš PEŠEK (203 Czech Republic), Jana KREJČÍ (203 Czech Republic), Jana SKŘIČKOVÁ (203 Czech Republic, belonging to the institution), Petr ZATLOUKAL (203 Czech Republic), Leona KOUBKOVÁ (203 Czech Republic), Ivona GRYGÁRKOVÁ (203 Czech Republic), Michal HRNČIARIK (203 Czech Republic) and Michal ŠTÍCHA (203 Czech Republic).
Edition Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer, 2011.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.661
RIV identification code RIV/00216224:14110/11:00052779
Organization unit Faculty of Medicine
ISSN 1556-0864
UT WoS 000291769801150
Keywords in English NSCLC; erlotinib; clinical predictors
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 15/9/2011 13:57.
Abstract
Erlotinib is a tyrosine-kinase inhibitor (TKI) used for the treatment of patients with non small cell lung cancer (NSCLC) in Czech Republic since 2005. Wide use of erlotinib in patients with NSCLC enables to collect a robust data in Czech Tarceva patients registry, where are recorded all the patients treated with erlotinib in 10 centers of excellence in Czech Rep. Objective of this retrospective analysis is to compare treatment efficacy in the subgroup of patients outside the clinical studies and try to find factors influencing the treatment effect.
PrintDisplayed: 24/5/2024 07:46